158 related articles for article (PubMed ID: 32414751)
1. FGFR2c Mesenchymal Isoform Expression Is Associated with Poor Prognosis and Further Refines Risk Stratification within Endometrial Cancer Molecular Subtypes.
Sengal AT; Patch AM; Snell CE; Smith DS; Leung SCY; Talhouk A; Williams ED; McAlpine JN; Pollock PM
Clin Cancer Res; 2020 Sep; 26(17):4569-4580. PubMed ID: 32414751
[TBL] [Abstract][Full Text] [Related]
2. Spatial expression of the FGFR2b splice isoform and its prognostic significance in endometrioid endometrial carcinoma.
Sengal AT; Smith D; Snell CE; Leung S; Talhouk A; Williams ED; McAlpine JN; Pollock PM
J Pathol Clin Res; 2022 Nov; 8(6):521-537. PubMed ID: 35866380
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic characteristics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening.
Carr C; Son J; Yao M; Priyadarshini A; Marquard J; Vargas R; Michener C; AlHilli MM
Gynecol Oncol; 2020 Dec; 159(3):712-720. PubMed ID: 33046272
[TBL] [Abstract][Full Text] [Related]
4. TCGA molecular subgroups of endometrial carcinoma in ovarian endometrioid carcinoma: A quantitative systematic review.
D'Alessandris N; Travaglino A; Santoro A; Arciuolo D; Scaglione G; Raffone A; Inzani F; Zannoni GF
Gynecol Oncol; 2021 Nov; 163(2):427-432. PubMed ID: 34446267
[TBL] [Abstract][Full Text] [Related]
5. Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification.
Kim SR; Cloutier BT; Leung S; Cochrane D; Britton H; Pina A; Storness-Bliss C; Farnell D; Huang L; Shum K; Lum A; Senz J; Lee CH; Gilks CB; Hoang L; McAlpine JN
Gynecol Oncol; 2020 Jul; 158(1):3-11. PubMed ID: 32331700
[TBL] [Abstract][Full Text] [Related]
6. Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma.
Krämer P; Talhouk A; Brett MA; Chiu DS; Cairns ES; Scheunhage DA; Hammond RFL; Farnell D; Nazeran TM; Grube M; Xia Z; Senz J; Leung S; Feil L; Pasternak J; Dixon K; Hartkopf A; Krämer B; Brucker S; Heitz F; du Bois A; Harter P; Kommoss FKF; Sinn HP; Heublein S; Kommoss F; Vollert HW; Manchanda R; de Kroon CD; Nijman HW; de Bruyn M; Thompson EF; Bashashati A; McAlpine JN; Singh N; Tinker AV; Staebler A; Bosse T; Kommoss S; Köbel M; Anglesio MS
Clin Cancer Res; 2020 Oct; 26(20):5400-5410. PubMed ID: 32737030
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast Growth Factor Receptor 2 Isoforms Detected via Novel RNA ISH as Predictive Biomarkers for Progestin Therapy in Atypical Hyperplasia and Low-Grade Endometrial Cancer.
Sengal AT; Smith D; Rogers R; Snell CE; Williams ED; Pollock PM
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33916719
[TBL] [Abstract][Full Text] [Related]
8. Less correlation between mismatch repair proteins deficiency and decreased expression of HLA class I molecules in endometrial carcinoma: a different propensity from colorectal cancer.
Mariya T; Kubo T; Hirohashi Y; Yanagawa J; Tabuchi Y; Matsuo K; Furumura K; Morita R; Nakatsugawa M; Kanaseki T; Tsukahara T; Hasegawa T; Saito T; Torigoe T
Med Mol Morphol; 2021 Mar; 54(1):14-22. PubMed ID: 32410009
[TBL] [Abstract][Full Text] [Related]
9. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.
Talhouk A; McConechy MK; Leung S; Yang W; Lum A; Senz J; Boyd N; Pike J; Anglesio M; Kwon JS; Karnezis AN; Huntsman DG; Gilks CB; McAlpine JN
Cancer; 2017 Mar; 123(5):802-813. PubMed ID: 28061006
[TBL] [Abstract][Full Text] [Related]
10. Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma.
Britton H; Huang L; Lum A; Leung S; Shum K; Kale M; Burleigh A; Senz J; Yang W; McConechy M; Kommoss S; Brucker S; Talhouk A; Gilks CB; McAlpine JN
Gynecol Oncol; 2019 Jun; 153(3):487-495. PubMed ID: 30922603
[TBL] [Abstract][Full Text] [Related]
11. GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study.
Brooks RA; Tritchler DS; Darcy KM; Lankes HA; Salani R; Sperduto P; Guntupalli S; DiSilvestro P; Kesterson J; Olawaiye AB; Moxley K; Waggoner S; Santin A; Rader JS; Kizer NT; Thaker PH; Powell MA; Mutch DG; Birrer MJ; Goodfellow PJ
Gynecol Oncol; 2019 May; 153(2):335-342. PubMed ID: 30827726
[TBL] [Abstract][Full Text] [Related]
12. POLE mutation combined with microcystic, elongated and fragmented (MELF) pattern invasion in endometrial carcinomas might be associated with poor survival in Chinese women.
He D; Wang H; Dong Y; Zhang Y; Zhao J; Lv C; Zheng X; Li D; Li T
Gynecol Oncol; 2020 Oct; 159(1):36-42. PubMed ID: 32800323
[TBL] [Abstract][Full Text] [Related]
13. Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study.
Kim SR; Tone A; Kim RH; Cesari M; Clarke BA; Eiriksson L; Hart T; Aronson M; Holter S; Lytwyn A; Lajkosz K; Oldfield L; Gallinger S; Bernardini MQ; Oza AM; Djordjevic B; Lerner-Ellis J; Van de Laar E; Vicus D; Pugh T; Pollett A; Ferguson SE
Gynecol Oncol; 2021 Apr; 161(1):221-227. PubMed ID: 33478752
[TBL] [Abstract][Full Text] [Related]
14. Clear cell endometrial carcinomas with mismatch repair deficiency have a favorable prognosis: A systematic review and meta-analysis.
Travaglino A; Raffone A; Santoro A; Raimondo D; Angelico G; Valente M; Arciuolo D; Scaglione G; D'alessandris N; Casadio P; Inzani F; Mollo A; Seracchioli R; Zannoni GF
Gynecol Oncol; 2021 Sep; 162(3):804-808. PubMed ID: 34266691
[TBL] [Abstract][Full Text] [Related]
15. FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
Jeske YW; Ali S; Byron SA; Gao F; Mannel RS; Ghebre RG; DiSilvestro PA; Lele SB; Pearl ML; Schmidt AP; Lankes HA; Ramirez NC; Rasty G; Powell M; Goodfellow PJ; Pollock PM
Gynecol Oncol; 2017 May; 145(2):366-373. PubMed ID: 28314589
[TBL] [Abstract][Full Text] [Related]
16. Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer.
Chung YS; Woo HY; Lee JY; Park E; Nam EJ; Kim S; Kim SW; Kim YT
Am J Obstet Gynecol; 2021 Apr; 224(4):370.e1-370.e13. PubMed ID: 33039397
[TBL] [Abstract][Full Text] [Related]
17. Women 50 years or younger with endometrial cancer: the argument for universal mismatch repair screening and potential for targeted therapeutics.
Ring KL; Connor EV; Atkins KA; Ricketts W; Kashlan B; Modesitt SC
Int J Gynecol Cancer; 2013 Jun; 23(5):853-60. PubMed ID: 23552806
[TBL] [Abstract][Full Text] [Related]
18. Expression of the FGFR2c mesenchymal splicing variant in human keratinocytes inhibits differentiation and promotes invasion.
Ranieri D; Rosato B; Nanni M; Belleudi F; Torrisi MR
Mol Carcinog; 2018 Feb; 57(2):272-283. PubMed ID: 29068468
[TBL] [Abstract][Full Text] [Related]
19. Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas.
Zhao Q; Caballero OL; Davis ID; Jonasch E; Tamboli P; Yung WK; Weinstein JN; ; Strausberg RL; Yao J
Clin Cancer Res; 2013 May; 19(9):2460-72. PubMed ID: 23444225
[TBL] [Abstract][Full Text] [Related]
20. Altered expression of fibroblast growth factor receptor 2 isoform IIIc: relevance to endometrioid adenocarcinoma carcinogenesis and histological differentiation.
Peng WX; Kudo M; Fujii T; Teduka K; Naito Z
Int J Clin Exp Pathol; 2014; 7(3):1069-76. PubMed ID: 24696723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
